{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:21:19Z","timestamp":1785338479972,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Endosc"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Optimized drug delivery systems are needed for intraperitoneal chemotherapy. The aim of this study was to develop a technology for applying pressurized intraperitoneal aerosol chemotherapy (PIPAC) under hyperthermic conditions (hPIPAC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is an ex-vivo study in an inverted bovine urinary bladder (IBUB). Hyperthermia was established using a modified industry-standard device (Humigard). Two entry and one exit ports were placed. Warm-humid CO<jats:sub>2<\/jats:sub> was insufflated in the IBUB placed in a normothermic bath to simulate body thermal inertia. The temperature of the aerosol, tissue, and water bath was measured in real-time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Therapeutic hyperthermia (target tissue temperature 41\u201343\u00a0\u00b0C) could be established and maintained over 30\u00a0min. In the first phase (insufflation phase), tissue hyperthermia was created by insufflating continuously warm-humid CO<jats:sub>2<\/jats:sub>. In the second phase (aerosolization phase), chemotherapeutic drugs were heated up and aerosolized into the IBUB. In a third phase (application phase), hyperthermia was maintained within the therapeutic range using an endoscopic infrared heating device. In a fourth phase, the toxic aerosol was discarded using a closed aerosol waste system (CAWS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>We introduce a simple and effective technology for hPIPAC. hPIPAC is feasible in an ex-vivo model by using a combination of industry-standard medical devices after modification. Potential pharmacological and biological advantages of hPIPAC over PIPAC should now be evaluated.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00464-021-08567-y","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T16:23:17Z","timestamp":1623342197000},"page":"6358-6365","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Technology development of hyperthermic pressurized intraperitoneal aerosol chemotherapy (hPIPAC)"],"prefix":"10.1007","volume":"35","author":[{"given":"C.","family":"Bachmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Sautkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Nadiradze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Archid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. J.","family":"Weinreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"K\u00f6nigsrainer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5521-6237","authenticated-orcid":false,"given":"M. A.","family":"Reymond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"8567_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.7453\/gahmj.2012.1.1.016","volume":"1","author":"GS Kienle","year":"2012","unstructured":"Kienle GS (2012) Fever in cancer treatment: Coley\u2019s therapy and epidemiologic observations. Glob Adv Health Med 1:92\u2013100","journal-title":"Glob Adv Health Med"},{"key":"8567_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S1040-8428(01)00179-2","volume":"43","author":"B Hildebrandt","year":"2002","unstructured":"Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G, Kerner T, Felix R, Riess H (2002) The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol 43:33\u201356","journal-title":"Crit Rev Oncol Hematol"},{"key":"8567_CR3","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1615\/CritRevBiomedEng.v38.i1.80","volume":"38","author":"W Rao","year":"2010","unstructured":"Rao W, Deng ZS, Liu J (2010) A review of hyperthermia combined with radiotherapy\/chemotherapy on malignant tumors. Crit Rev Biomed Eng 38:101\u2013116","journal-title":"Crit Rev Biomed Eng"},{"key":"8567_CR4","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.ejso.2016.02.250","volume":"42","author":"D Cecchin","year":"2016","unstructured":"Cecchin D, Negri A, Frigo AC, Bui F, Zucchetta P, Bodanza V, Gregianin M, Campana LG, Rossi CR, Rastrelli M (2016) Calculating regional tissue volume for hyperthermic isolated limb perfusion: four methods compared. Eur J Surg Oncol 42:1898\u20131905","journal-title":"Eur J Surg Oncol"},{"key":"8567_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-4613-1245-1_3","volume":"81","author":"AD Stephens","year":"1996","unstructured":"Stephens AD, Belliveau JF, Sugarbaker PH (1996) Intraoperative hyperthermic lavage with cisplatin for peritoneal carcinomatosis and sarcomatosis. Cancer Treat Res 81:15\u201330","journal-title":"Cancer Treat Res"},{"key":"8567_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1515\/pp-2017-0010","volume":"2","author":"E de Bree","year":"2017","unstructured":"de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O (2017) Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura Peritoneum 2:47\u201362","journal-title":"Pleura Peritoneum"},{"key":"8567_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00104-019-0982-5","volume":"90","author":"H Leebmann","year":"2019","unstructured":"Leebmann H, Piso P (2019) Hypertherme intraperitoneale chemotherapie. Chirurg 90:593\u2013604","journal-title":"Chirurg"},{"issue":"2","key":"8567_CR8","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1515\/pp-2017-0004","volume":"1","author":"M Steuperaert","year":"2017","unstructured":"Steuperaert M, Debbaut C, Segers P, Ceelen W (2017) Modelling drug transport during intraperitoneal chemotherapy. Pleura Peritoneum 1(2):73\u201383","journal-title":"Pleura Peritoneum"},{"key":"8567_CR9","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1097\/SLA.0b013e3182582b38","volume":"256","author":"O Facy","year":"2012","unstructured":"Facy O, Al Samman S, Magnin G, Ghiringhelli F, Ladoire S, Chauffert B, Rat P, Ortega-Deballon P (2012) High pressure enhances the effect of hyperthermia in intraperitoneal chemotherapy with oxaliplatin: an experimental study. Ann Surg 256:1084\u20131088","journal-title":"Ann Surg"},{"key":"8567_CR10","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ejso.2018.08.023","volume":"45","author":"F Gremonprez","year":"2019","unstructured":"Gremonprez F, Gossye H, Ceelen W (2019) Use of hyperthermia versus normothermia during intraperitoneal chemoperfusion with oxaliplatin for colorectal peritoneal carcinomatosis: a propensity score matched analysis. Eur J Surg Oncol 45:366\u2013370","journal-title":"Eur J Surg Oncol"},{"key":"8567_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Qu\u00e9net","year":"2021","unstructured":"Qu\u00e9net F, Elias D, Roca L, Go\u00e9r\u00e9 D, Ghouti L, Pocard M et al (2021) Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 22:256\u2013266","journal-title":"Lancet Oncol"},{"key":"8567_CR12","doi-asserted-by":"publisher","first-page":"20180131","DOI":"10.1515\/pp-2018-0131","volume":"3","author":"A K\u00f6nigsrainer","year":"2018","unstructured":"K\u00f6nigsrainer A, Rau B (2018) Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): don\u2019t throw the baby out with the bathwater. Pleura Peritoneum 3:20180131","journal-title":"Pleura Peritoneum"},{"key":"8567_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s004649900010","volume":"14","author":"MA Reymond","year":"2000","unstructured":"Reymond MA, Hu B, Garcia A, Reck T, K\u00f6ckerling F, Hess J et al (2000) Feasibility of therapeutic pneumoperitoneum in a large animal model using a microvaporisator. Surg Endosc 14:51\u201355","journal-title":"Surg Endosc"},{"key":"8567_CR14","unstructured":"Capnomed: Laparoscopic Nebulizer for Liquids - Capnopen. Available at: https:\/\/www.capnomed.de\/en\/.2018. Accessed 12 Feb 2021"},{"key":"8567_CR15","doi-asserted-by":"publisher","first-page":"e368","DOI":"10.1016\/S1470-2045(19)30318-3","volume":"20","author":"M Alyami","year":"2019","unstructured":"Alyami M, H\u00fcbner M, Grass F, Bakrin N, Villeneuve L, Laplace N et al (2019) Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol 20:e368\u2013e377","journal-title":"Lancet Oncol"},{"key":"8567_CR16","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1007\/s00464-015-4738-0","volume":"30","author":"H Jung do","year":"2016","unstructured":"Jung do H, Son SY, Oo AM, Park YS, Shin DJ, Ahn SH, Park do J, Kim HH (2016) Feasibility of hyperthermic pressurized intraperitoneal aerosol chemotherapy in a porcine model. Surg Endosc 30:4258\u20134264","journal-title":"Surg Endosc"},{"key":"8567_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1515\/pp-2017-0018","volume":"2","author":"W Willaert","year":"2017","unstructured":"Willaert W, Sessink P, Ceelen W (2017) Occupational safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC). Pleura Peritoneum 2:121\u2013128","journal-title":"Pleura Peritoneum"},{"key":"8567_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1515\/pp-2016-0019","volume":"1","author":"M Graversen","year":"2016","unstructured":"Graversen M, Pedersen PB, Mortensen MB (2016) Environmental safety during the administration of pressurized intraperitoneal aerosol chemotherapy (PIPAC). Pleura Peritoneum 1:203\u2013208","journal-title":"Pleura Peritoneum"},{"issue":"2","key":"8567_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1515\/pp-2017-0006","volume":"1","author":"D Schnelle","year":"2017","unstructured":"Schnelle D, Weinreich FJ, Kibat J, Reymond MA (2017) A new ex vivo model for optimizing distribution of therapeutic aerosols: the (inverted) bovine urinary bladder. Pleura Peritoneum 1(2):37\u201341","journal-title":"Pleura Peritoneum"},{"key":"8567_CR20","doi-asserted-by":"publisher","first-page":"20190017","DOI":"10.1515\/pp-2019-0017","volume":"4","author":"I Sautkin","year":"2019","unstructured":"Sautkin I, Solass W, Weinreich FJ, K\u00f6nigsrainer A, Schenk M, Thiel K, Reymond MA (2019) A real-time ex vivo model (eIBUB) for optimizing intraperitoneal drug delivery as an alternative to living animal models. Pleura Peritoneum 4:20190017","journal-title":"Pleura Peritoneum"},{"key":"8567_CR21","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1097\/SLE.0000000000000001","volume":"24","author":"JV Roth","year":"2014","unstructured":"Roth JV, Sea S (2014) An assessment by calorimetric calculations of the potential thermal benefit of warming and humidification of insufflated carbon dioxide. Surg Laparosc Endosc Percutaneous Tech 24:e106\u2013e109","journal-title":"Surg Laparosc Endosc Percutaneous Tech"},{"key":"8567_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1080\/02656730701344520","volume":"23","author":"HP Kok","year":"2007","unstructured":"Kok HP, van Haaren PM, van de Kamer JB, Crezee J (2007) Theoretical comparison of intraluminal heating techniques. Int J Hyperth 23:395\u2013411","journal-title":"Int J Hyperth"},{"key":"8567_CR23","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.3762\/bjnano.8.272","volume":"8","author":"D G\u00f6hler","year":"2017","unstructured":"G\u00f6hler D, Gro\u00dfe S, Bellendorf A, Falkenstein TA, Ouaissi M, Zieren J et al (2017) Hyperthermic intracavitary nanoaerosol therapy (HINAT) as an improved approach for pressurised intraperitoneal aerosol chemotherapy (PIPAC): Technical description, experimental validation and first proof of concept. Beilstein J Nanotechnol 8:2729\u20132740","journal-title":"Beilstein J Nanotechnol"},{"key":"8567_CR24","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1016\/j.ejso.2019.06.018","volume":"45","author":"W Willaert","year":"2019","unstructured":"Willaert W, Van de Sande L, Van Daele E, Van De Putte D, Van Nieuwenhove Y, Pattyn P, Ceelen W (2019) Safety and preliminary efficacy of electrostatic precipitation during pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable carcinomatosis. Eur J Surg Oncol 45:2302\u20132309","journal-title":"Eur J Surg Oncol"},{"key":"8567_CR25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ejso.2019.08.024","volume":"46","author":"M Graversen","year":"2020","unstructured":"Graversen M, Detlefsen S, Ellebaek SB, Fristrup C, Pfeiffer P, Mortensen MB (2020) Pressurized intraperitoneal aerosol chemotherapy with one minute of electrostatic precipitation (ePIPAC) is feasible, but the histological tumor response in peritoneal metastasis is insufficient. Eur J Surg Oncol 46:155\u2013159","journal-title":"Eur J Surg Oncol"},{"key":"8567_CR26","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-020-09332-6","author":"A Taibi","year":"2020","unstructured":"Taibi A, Teixeira Farinha H, Durand Fontanier S, Sayedalamin Z, H\u00fcbner M, Sgarbura O (2020) Pressurized intraperitoneal aerosol chemotherapy enhanced by electrostatic precipitation (ePIPAC) for patients with peritoneal metastases. Ann Surg Oncol. https:\/\/doi.org\/10.1245\/s10434-020-09332-6","journal-title":"Ann Surg Oncol"},{"key":"8567_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1245\/s10434-020-08743-9","volume":"28","author":"RJ Lurvink","year":"2021","unstructured":"Lurvink RJ, Tajzai R, Rovers KP, Wassenaar ECE, Moes DAR, Pluimakers G et al (2021) Systemic pharmacokinetics of oxaliplatin after intraperitoneal administration by electrostatic pressurized intraperitoneal aerosol chemotherapy (ePIPAC) in patients with unresectable colorectal peritoneal metastases in the CRC-PIPAC trial. Ann Surg Oncol 28:265\u2013272","journal-title":"Ann Surg Oncol"}],"container-title":["Surgical Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-021-08567-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00464-021-08567-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-021-08567-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T01:36:41Z","timestamp":1634607401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00464-021-08567-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":27,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["8567"],"URL":"https:\/\/doi.org\/10.1007\/s00464-021-08567-y","relation":{},"ISSN":["0930-2794","1432-2218"],"issn-type":[{"value":"0930-2794","type":"print"},{"value":"1432-2218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"18 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MAR is the holder of several patents on PIPAC technology and shareholder of Capnomed GmbH, Villingendorf, Germany. The other authors have no potential conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}